Ascorbic acid is neuroprotective against global ischaemia in striatum but not hippocampus: histological and voltammetric data.
Following reports that ascorbic acid (AA) blocks NMDA receptors, we examined its possible neuroprotective properties in vivo (gerbil bilateral carotid artery occlusion model: BCAO) and in vitro (ischaemia-induced dopamine (DA) release in brain slices). Five minutes of BCAO caused substantial cell loss of 90-95% and 40-50% in gerbil CA1 hippocampus and striatum, respectively, measured in haematoxylin and eosin-stained sections, 5 days post-insult. AA (500 mg kg(-1) day(-1) i.p. for 312 days, first dose 1 h before occlusion) significantly (P<0.05) reduced striatal cell loss (from 40 to 13%) while only reducing CA1 cell loss from 95 to 88%. A lower dose (250 mg kg(-1) day(-1) i.p. for 312 days) was ineffective in either region. AA (750 mg kg(-1) day(-1) i.p. for 312 days) caused significant striatal protection (cell loss reduced from 49 to 20%) if treatment was initiated 1 h before occlusion. Initiation of treatment immediately post occlusion did not cause significant protection. Neither treatment regime protected CA1 hippocampus. In separate experiments we examined the effect of AA on DA release, monitored by voltammetry, in an in vitro model of striatal ischaemia. Four DA release variables were measured: T(on)--time from initiation of ischaemia to the onset of DA release, T(pk)--the time from onset of DA release to maximum, deltaDA/deltat--the mean rate of DA release and [DA](max)-- the maximum extracellular DA concentration. Control values in drug-naive slices were: T(on)=193+/-8 s, T(pk) = 24 +/- 4 s, [DA](max) = 69 +/- 6 microM and deltaDA/deltat = 4.2 +/- 0.7 microM s(-1) (means+/-S.E.M., n=15). 212 h pretreatment with AA (0.4 to 10 mM) did not affect T(on) or [DA](max) but increased T(pk) and decreased deltaDA/deltat (P<0.05) with an EC50 of 1.66 mM. NMDA (100 microM) shortened T(on). N-ethylmaleimide (20 microM) had no effect on the response to AA but potentiated the action of NMDA on T(on). AA (2 or 10 mM) had no effect on the response to NMDA. We conclude that AA is neuroprotective against global ischaemia in the striatum and that some of this action may be due to attenuation of ischaemia-induced DA release. This action is mediated neither by blockade of the NMDA receptor nor modulation of its redox status.
Stamford
J A
JA
Neurotransmission Laboratory, Academic Department of Anaesthesia and Intensive Care, St. Bartholomew's and the Royal London School of Medicine and Dentistry, Alexandra Wing, Royal London Hospital, Whitechapel, London, E1 1BB, UK. j.a.stamford@mds.qmw.ac.uA
Isaac
D
D
Hicks
C A
CA
Ward
M A
MA
Osborne
D J
DJ
O'Neill
M J
MJ
D000477:Alkylating Agents / Q000494:pharmacology; D000818:Animals; D001205:Ascorbic Acid / Q000627:therapeutic use*; D002545:Brain Ischemia / Q000188:drug therapy*; D003342:Corpus Striatum / Q000098:blood supply / Q000187:drug effects*; D004298:Dopamine / Q000378:metabolism; D004347:Drug Interactions; D004563:Electrochemistry / Q000379:methods; D005033:Ethylmaleimide / Q000494:pharmacology; D005849:Gerbillinae; D006624:Hippocampus / Q000098:blood supply / Q000187:drug effects*; D008297:Male; D016202:N-Methylaspartate / Q000494:pharmacology; D009410:Nerve Degeneration; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar
D000477:Alkylating Agents; D018696:Neuroprotective Agents; D016202:N-Methylaspartate; D005033:Ethylmaleimide; D001205:Ascorbic Acid; D004298:Dopamine